Viracta Therapeutics (VIRX) Revenue & Revenue Breakdown
Viracta Therapeutics Revenue Highlights
Viracta Therapeutics Revenue by Period
Viracta Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $120.00K | -94.21% |
| 2019-12-31 | $2.07M | 774.68% |
| 2018-12-31 | $237.00K | -64.57% |
| 2017-12-31 | $669.00K | -73.62% |
| 2016-12-31 | $2.54M | -17.15% |
| 2015-12-31 | $3.06M | -46.62% |
| 2014-12-31 | $5.73M | -27.93% |
| 2013-12-31 | $7.96M | 111.93% |
| 2012-12-31 | $3.75M | -24.92% |
| 2011-12-31 | $5.00M | 15013.50% |
| 2010-12-31 | $33.08K | -99.12% |
| 2009-12-31 | $3.76M | -30.56% |
| 2008-12-31 | $5.42M | -43.94% |
| 2007-12-31 | $9.66M | -29.51% |
| 2006-12-31 | $13.71M | -17.02% |
| 2005-12-31 | $16.52M | - |
Viracta Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Viracta Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $738.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $120.00K | -94.21% |
| 2019-12-31 | $2.07M | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | -100.00% |
| 2018-03-31 | $237.00K | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | -100.00% |
| 2017-03-31 | $669.00K | -1.04% |
| 2016-12-31 | $676.00K | 10.82% |
| 2016-09-30 | $610.00K | - |
| 2016-06-30 | $610.00K | -4.69% |
| 2016-03-31 | $640.00K | -4.48% |
| 2015-12-31 | $670.00K | -1.90% |
| 2015-09-30 | $683.00K | -20.02% |
| 2015-06-30 | $854.00K | - |
| 2015-03-31 | $854.00K | -4.69% |
| 2014-12-31 | $896.00K | 4.92% |
| 2014-09-30 | $854.00K | -57.06% |
| 2014-06-30 | $1.99M | -0.30% |
| 2014-03-31 | $2.00M | 0.30% |
| 2013-12-31 | $1.99M | - |
| 2013-09-30 | $1.99M | - |
| 2013-06-30 | $1.99M | - |
| 2013-03-31 | $1.99M | - |
| 2012-12-31 | $1.99M | 650.57% |
| 2012-09-30 | $265.00K | -82.33% |
| 2012-06-30 | $1.50M | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | -100.00% |
| 2011-09-30 | $1.00M | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2011-03-31 | $4.00M | 66566.67% |
| 2010-12-31 | $6.00K | 100.00% |
| 2010-09-30 | - | -100.00% |
| 2010-06-30 | $14.58K | 16.66% |
| 2010-03-31 | $12.50K | - |
| 2009-12-31 | $12.50K | - |
| 2009-09-30 | $12.50K | -99.64% |
| 2009-06-30 | $3.51M | 1467.75% |
| 2009-03-31 | $224.05K | 1692.38% |
| 2008-12-31 | $12.50K | -97.55% |
| 2008-09-30 | $510.42K | -80.30% |
| 2008-06-30 | $2.59M | 12.51% |
| 2008-03-31 | $2.30M | 12.53% |
| 2007-12-31 | $2.05M | 11.83% |
| 2007-09-30 | $1.83M | - |
Viracta Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Viracta Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EYPT | EyePoint Pharmaceuticals | $46.02M | $9.48M |
| BCYC | Bicycle Therapeutics | $26.98M | $9.36M |
| SQZ | SQZ Bio | $21.03M | - |
| MREO | Mereo BioPharma Group | $10.00M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| IGMS | IGM Biosciences | $2.13M | $497.00K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| ALXO | ALX Oncology | - | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| CABA | Cabaletta Bio | - | - |
| RLYB | Rallybio | - | $299.00K |
| TARA | Protara Therapeutics | - | - |
| INZY | Inozyme Pharma | - | - |
| LPTX | Leap Therapeutics | - | - |
| VIRX | Viracta Therapeutics | - | - |
| BMEA | Biomea Fusion | - | - |
| TRVI | Trevi Therapeutics | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| VINC | Vincerx Pharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| TNYA | Tenaya Therapeutics | - | - |
VIRX Revenue FAQ
What is Viracta Therapeutics’s yearly revenue?
Viracta Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. VIRX's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Viracta Therapeutics’s quarterly revenue?
Viracta Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). VIRX's quarterly revenue for Q4 2023 was $738K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Viracta Therapeutics’s revenue growth rate?
Viracta Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -100.00%.